NEW YORK (AP) — Wall Street is holding near its record heights on Monday, ahead of a week likely to be dominated by updates ...

In a significant breakthrough for the treatment of liver disease, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in ...

Viking Therapeutics' weight-loss pill trial results underwhelmed, causing a sharp decline in shares. Meanwhile, Novo Nordisk's liver disease approval for Wegovy uplifted its stock. European corporate ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Viking Therapeutics, Inc.'s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock ...

A group of vaccine-skeptical doctors and mandate opponents is challenging the CDC’s childhood immunization schedule in ...

The AHA’s new 2025 blood pressure guidelines emphasize lifestyle changes, stress management, and medication to help prevent ...

Novo Nordisk (NYSE: NVO) stock is up 2.2% through 10:30 a.m. ET on Viking's bad news. Where to invest $1,000 right now? Our ...

Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...

Recent developments in weight-loss treatments have impacted the market significantly. Viking Therapeutics' new pill showed ...